ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report
These cases expand the landscape of noncanonical <i>ALK</i> fusions in NSCLC which are responsive to approved ALK TKIs and offer insights into oncogenic and resistance mechanisms. Comprehensive molecular workup, including RNA-based NGS, is essential for detecting rare but actionable ALK rearrangements and optimizing therapeutic strategy. NGS of CSF was a valuable tool for the detection of clinically suspected leptomeningeal disease and disease monitoring.
Authors
- Mohamed A. Yakoub (ORCID: https://orcid.org/0000-0002-6400-660X)
- Michael David Offin (ORCID: https://orcid.org/0000-0002-7959-3018)
- Juliana Eng (ORCID: https://orcid.org/0000-0002-7630-3054)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Charles Hsu (ORCID: https://orcid.org/0000-0003-1036-9015)
- Soo-Ryum Yang
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100934
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute